Tisagenlecleucel is the first and currently the only CAR-T cell therapy approved in Hong Kong, which was registered with Hong Kong’s Department of Health under the Pharmacy and Poisons Ordinance on 5 March 2020. Specifically, the treatment is applicable to the following: